Bespak launches Syrina 2.25 auto injector
The new Syrina 2.25 is one of the most compact versions of auto-injector available today utilising the standard 2.25 mL PFS, based on Bespak’s proprietary VapourSoft technology.
Bespak has launched Syrina 2.25 at PDA Europe 2015. Moreover, Steven Kaufman, Global Business Development Lead at the company, will chair a 1-day specialized industry discussion on innovative combinational products at a workshop taking place during the renowned PDA Europe 2015 Universe of Pre-filled Syringes & Injection Devices in Vienna, Austria.
Key focus areas to be addressed at the workshop include advanced technologies in the field of self-injection devices, ranging from auto, pen, bolus and wearable-injectors through to pumps. Above all, the event will focus on how innovation in the design of combination products will help overcome industry challenges, improve compliance and enhance the patient experience.
Moreover, the discussion will focus on insights into how primary containers, such as prefilled syringes and cartridges, both in plastic and in glass form, can be effectively integrated into such devices. Overcoming challenges and implementing effective approaches for successfully taking combinational products to market also forms a significant part of the workshop’s agenda.
Leading biopharmaceutical companies and related suppliers are set to take part in the workshop and will share industry experiences and discuss the technology behind devices used in today’s growing field of combination products. Bespak has chosen this event to launch the latest addition to the Syrina product range, Syrina 2.25. This new product will highlight how flexible the technology is, directly addressing the need for higher volume and higher viscous solutions. The Syrina range of self-injection devices, which span assisted syringes with needle safety features through to fully functioning auto-injectors, all utilise Bespak’s proven VapourSoft powerpack system.
Commenting on Bespak’s involvement in chairing the workshop, Steven Kaufman commented: “We are pleased to have this opportunity to lead industry discussion on the transformational impact, for the drug delivery device sector and for patients, of innovation in the field of combinational products. Indeed, at Bespak, we are committed to the development of advanced, problem solving technology and therefore welcome this forum for sharing insights. The PDA is a great organization and provides us with an excellent forum.”
Remarking on the launch of Syrina 2.25, Steven Kaufman said: “We are also excited to unveil our newest addition to the Syrina offering. This new product will be available for exclusive demo in Vienna and to biopharmaceutical companies that would like to conduct studies to learn more about the technology first hand. We look forward to the Vienna event.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance